Overview of Dr. Crawford
Dr. Carl Crawford is a gastroenterologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and Memorial Sloan Kettering Cancer Center. He received his medical degree from Yale School of Medicine and has been in practice 16 years. He is one of 300 doctors at New York-Presbyterian Hospital and one of 35 doctors at Memorial Sloan Kettering Cancer Center who specialize in Gastroenterology. He has more than 40 publications and over 500 citings.
Office
1305 York Ave 4th Floor
New York, NY 10021
Education & Training
- Yale School of MedicineClass of 2001
- Memorial Sloan Kettering Cancer CenterFellowship, Advanced Endoscopy
Certifications & Licensure
- NY State Medical License 2004 - 2027
Clinical Trials
- SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
Publications & Presentations
PubMed
- Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.Paul Feuerstadt, Carl V Crawford, Xing Tan, Victoria Pokhilko, Lindy Bancke
Journal of Clinical Gastroenterology. 2024-09-01 - Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non-Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study.Kelly R Reveles, Anne J Gonzales-Luna, Yoav Golan, Carolyn D Alonso, Beth Guthmueller
Open Forum Infectious Diseases. 2024-07-01 - The Gut-Brain Axis in Parkinson's Disease.Virginia Gao, Carl V Crawford, Jacqueline Burré
Cold Spring Harbor Perspectives in Medicine. 2024-05-21
Journal Articles
- To Scope or Not to Scope? The Safety of Upper Endoscopy in the Setting of Pulmonary EmbolismRussell Rosenblatt, Zaid Tafesh, David Wan, Carl Crawford, Nature
- Gut Microbiota Dysbiosis and Diarrhea in Kidney Transplant RecipientsEric Pamer, Manikkam Suthanthiran, Ying Taur, Michael J Satlin, Darshana Dadhania, John Richard Lee, Carl Crawford, Michelle Lubetzky, American journal of transplantation
Press Mentions
- Vowst Becomes First FDA-Approved Fecal Microbiota PillApril 27th, 2023
- FDA OKs First Poop-Based Oral TherapyApril 27th, 2023
- Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (Fecal Microbiota Spores, Live-Brpk) for Prevention of Recurrence of C. Difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDIApril 26th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: